Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Immunicum AB. (12/13/19). "Press Release: Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO".

Organisations Organisation Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)
  Group Immunicum (Group)
  Organisation 2 Merck KGaA
  Group Merck (DE) (Group)
Products Product ilixadencel
  Product 2 cancer immunotherapy (immuno-oncology, I-O)
Persons Person de Sousa, Carlos (Immunicum 201610– CEO before Zealand Pharma + Nycomed/Takeda + Pfizer + Novartis + BBB Therapeutics)
  Person 2 Oredsson, Michael (BioInvent 201310 CEO before CEO at Probi AB before Pharmacia)

The Board of Directors of Immunicum announced today that, by mutual agreement, Carlos de Sousa has resigned as CEO of Immunicum effective immediately. The Board has appointed Alex Karlsson-Parra, Immunicum’s Chief Scientific Officer, as acting CEO. The Board will begin recruitment of a new CEO shortly.

“We thank Carlos for his efforts that have put Immunicum in a strong position, with competitive clinical results and a competent and experienced organization with the ability to develop the company further. Over the past three years as CEO, Carlos has significantly contributed to steering the company through a demanding phase in the development of the drug candidate ilixadencel. Now is the right time to let a new CEO take Immunicum through its next development phase,” said Michael Oredsson, Chairman of the Board of Immunicum.

Carlos de Sousa was appointed CEO of Immunicum in October 2016. During his tenure, the company has, among other things, completed the liver cancer study (HCC), listed on Nasdaq Stockholm, initiated the multi-indication study ILIAD and entered into an agreement with Merck KGaA and Pfizer to study ilixadencel in combination with avelumab as part of ILIAD as well as completed the GIST and MERECA studies with promising results.

As Alex Karlsson-Parra is appointed acting CEO, Immunicum's Senior Director of Business Development Sijme Zeilemaker has expanded his responsibility to the role of Chief Operating Officer. Immunicum's Board of Directors will shortly begin recruitment of a new CEO to realize ilixadencel’s potential and build Immunicum’s value.

The information is such information that Immunicum is obliged to make public pursuant to EU Market Abuse Regulation. The information was released for public disclosure through the contact persons detailed below on 13 December 2019 at 8.30 am CEST.

For more information, please contact:

Michael Oredsson, Chairman of the Board, Immunicum
Telefon: +61 416 717 971

Jonas Rodny
Paues Åberg Communications
Telefon: +46 76 190 90 51

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.

Record changed: 2019-12-19


Picture [iito] Made Without Love 650x80px

More documents for Immunicum (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top